Efficacy of Detoxsan® powder on diarrhea caused by gastrointestinal neuroendocrine tumors

Table 2 Clinical parameters of the patients

Patient	Nutricion	Somatostatin	Dosage	Interval	Loperamide1	Disease	NET type	Primary			Metastases	in		PRRT
	consultation	analog				stage			Liver	Lymph	Bone	Lung	Peritoneum
1	yes	OCT	30 mg	4 wk	if required	IV	functional	midgut	x	x			x	2nd
2	yes	OCT	20 mg	4 wk	if required	IIIb	functional	midgut	x	x			x	3rd
3	yes	OCT	30 mg	4 wk	no	IV	functional	midgut	x	x	x		x	2nd
4	yes	LAN	120 mg	6 wk	no	IV	functional	midgut	x	x	x	x		2nd
5	yes	LAN	120 mg	3 wk	no	IV	functional	midgut	x		x			2nd
6	yes	OCT	30 mg	4 wk	no	IIIb	functional	midgut	x	x				4th
7	yes	OCT	30 mg	4 wk	no	IIIb	functional	midgut	x	x				3rd
8	yes	LAN	120 mg	4 wk	if required	IV	functional	midgut	x	x				2nd
9	yes	no			no	IV	nonfunctional	pancreas	x	x	x			1st
10	yes	OCT	30 mg	4 wk	no	IV	functional	midgut	x	x	x			3rd
		OCT s.c.	+ 100 µg	if required
11	yes	OCT	30 mg	4 wk	no	IIIb	functional	midgut	x				x	1st
12	yes	LAN	120 mg	4 wk	if required	IV	functional	midgut		x				2nd
13	yes	OCT	30 mg	4 wk	if required	IV	functional	midgut	x					3rd
14	yes	LAN	120 mg	4 wk	no	IV	functional	appendix		x				2nd
15	yes	OCT	30 mg	4 wk	no	IV	functional	midgut	x	x			x	3rd
16	yes	OCT	20 mg	4 wk	if required	IV	functional	midgut	x				x	2nd
17	yes	LAN	120 mg	4 wk	if required	IIIb	functional	midgut	x	x	x			2nd
18	yes	OCT	30 mg	3 wk	if required	IV	functional	CUP	x	x				3rd
19	yes	OCT	30 mg	4 wk	no	IV	nonfunctional	pancreas	x		x		x	1st
20	yes	OCT	30 mg	4 wk	no	IV	functional	CUP	x	x				3rd

¹During treatment with Detoxsan^® powder. OCT: Octreotide (Sandostatin LAR); LAN: Lanreotide (Somatuline Autogel); CUP: Unknown primary with suspicion of midgut primary; PRRT: Peptide receptor radionuclide therapy as treatment line. Determination of the disease stage according to the WHO classification[29].